Safety and efficacy study of CF101 to treat psoriasis

Journal of Drugs in Dermatology, Jan, 2008

Sponsored by Can-Fite BioPharma. This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis.

Condition         Intervention  Phase

Plaque Psoriasis  Drug: CF101   Phase II

Study ID Numbers: CF101-201PS

ClinicalTrials.gov Identifier: NCT00428974

COPYRIGHT 2008 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here

Content provided in partnership with Thompson Gale